Study of the Fully Implanted Acclaim® Cochlear Implant

Overview

About this study

The purpose of this study is to demonstrate the safety and efficacy of the fully implanted Acclaim® cochlear implant for the treatment of severe to profound sensorineural hearing loss.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Signed and dated informed consent form.
  • Able to understand and comply with the requirements of the Study, including surgery and post-implant rehabilitation.
  • Ability to read, write, comprehend, and speak fluently in English.
  • Post-lingually deafened.
  • 18 years of age or older at the time of informed consent.
  • Good health and absence of significant comorbidities, in the opinion of the Principal Investigator.
  • At least 30 days of experience with appropriate bilaterally fit hearing aids.
  • Ear to be implanted has severe to profound hearing loss defined as pure tone average at 500, 1000, 2000 and 4000 Hz ≥ 70 dB.
  • Contralateral ear has moderately severe to profound hearing loss defined as pure tone average at 500, 1000, 2000 and 4000 Hz ≥ 60 dB.
  • Limited benefit from amplification defined as CNC monosyllabic word recognition ≤ 40% in the ear to be implanted and ≤ 60% in the contralateral ear, in the aided condition.
  • Normal middle ear function based on otoscopy and tympanometry. 
  • An accessible cochlear lumen and intact cochlear nerve, and no known lesions on the auditory nerve or auditory central nervous system, on the ear to be implanted confirmed with MRI or CT scan.

Exclusion Criteria:

  • Documented duration of severe to profound hearing loss for 20 or more years.
  • Previous cochlear implantation in either ear.
  • Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array.
  • Active external or middle ear pathology (i.e., infections, tympanic membrane perforation, or ossicular chain issues) in the ear to be implanted at the time of screening or in the past 6 months, that could impact the proper functioning of the device.
  • Known history of chronic eustachian tube dysfunction.
  • Prior surgery in the middle ear, inner ear, neck, or infraclavicular region which is anticipated to prevent proper placement or function of the Acclaim CI.
  • Hearing loss/disorder of retrocochlear origin.
  • Diagnosis of auditory neuropathy.
  • Currently using other active implants that are expected to interfere with the Acclaim CI position or function.
  • Known hypersensitivity to silicone rubber, polyurethane, stainless steel, titanium, platinum, or gold.
  • Known hypersensitivity or contraindications to procedural or post-procedural medications that cannot be adequately managed medically.
  • Pregnancy at the time of Acclaim CI implantation.
  • Known need for MRI or ionizing radiation treatment during Study participation.
  • nrealistic expectations on the Participant’s part regarding the possible benefits, risks, and limitations inherent to the surgical procedure and use of the Acclaim CI, in the Principal Investigator’s opinion.
  • Unwillingness or inability to comply with all investigational requirements. 
  • Additional conditions that would prevent completion of all Study requirements, in the opinion of the Principal Investigator.
  • Participation in an investigational drug study or another device study within 3 months of the Screening Visit.
  • Previous history of meningitis.
  • Deafness, in the ear to be implanted, due to:
    • a damaged or absent tympanic membrane,
    • a damaged or absent middle ear,
    • an absent cochlea,
    • lesions on the acoustic nerve, or
    • lesions on the central auditory pathway

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/11/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Colin Lea Driscoll, M.D.

Contact us for the latest status

Contact information:

Nicole Tombers R.N.

(507) 293-2445

Tombers.Nicole@mayo.edu

More information

Publications

Publications are currently not available